

## **PROXY FORM**

### **Annual General Meeting of Faron Pharmaceuticals Ltd 2021**

I/We, being shareholder(s) of Faron Pharmaceuticals Ltd, hereby appoint attorney-at-law Anniina Järvinen of Hannes Snellman Attorneys Ltd., or her order, as my/our proxy to vote on my/our behalf with all shares I/we hold in accordance with the voting instructions below at the Annual General Meeting of Faron Pharmaceuticals Ltd convened to be held on 23 April 2021.

Place and date:

---

Signature / signatures:

---

Print name / name of the legal person and its representative:

---

Personal identification number / business identity code:

---

Telephone number (daytime):

---

When you have completed and signed this proxy form, please send the proxy form by e-mail to [general.meeting@faron.com](mailto:general.meeting@faron.com) or by mail to Faron Pharmaceuticals Ltd, attn. Virve Nurmi, Joukahaisenkatu 6, FI-20520 Turku, Finland, by 19 April 2021 at 10:00 a.m. (EEST) at the latest. A shareholder who is a legal person shall in connection with the delivery of the proxy form and voting instructions deliver evidence of the proxy form signatory's right to represent the legal person (for example, a Trade Register extract or a certified copy of a board resolution).

Proxy documents in original shall be presented to the company upon request.

## **Voting Instructions**

Name of shareholder (print name): \_\_\_\_\_

To direct your proxy to vote with respect to the proposed resolution, please indicate the manner in which your proxy is to vote by checking (X) the appropriate box below.

**If you do not check any boxes below, your proxy will vote for the decision proposal contained in the notice to the Annual General Meeting published on 25 March 2021.**

“**Abstain from voting**” means giving an empty vote, in which case the shares are taken into account as shares represented in the handling of the agenda item, which has an impact with respect to resolutions requiring a qualified majority (e.g. agenda items 15 to 17). With respect to resolutions requiring a qualified majority, all shares represented at the Annual General Meeting are taken into account. Therefore, abstaining from voting has an impact on the outcome of the vote. Shareholders should be aware of this fact, especially if their intention is not to vote against the proposal.

	<b>Resolution item</b>	<b>For/Yes</b>	<b>Against/No</b>	<b>Abstain from voting</b>
7.	Adoption of the financial statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8.	Resolution on the use of the profit shown on the balance sheet and the payment of dividend	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9.	Resolution on the discharge of the members of the Board and the CEO of the Company from liability	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.	Resolution on the remuneration of the members of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11.	Resolution on the number of members of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12.	Election of members of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13.	Resolution on the remuneration of the auditor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14.	Election of the auditor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
15.	Resolution on the amendment of the Option Plan 2015	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.	Amendment of the Articles of Association	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
17.	Authorising the Board to decide on the issuance of shares, options or other special rights entitling to shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>